

WOAH Reference Laboratory Reports Activities 2025

This report has been submitted: 20 janvier 2026 16:31

LABORATORY INFORMATION

*Name of disease (or topic) for which you are a designated WOA Reference Laboratory:	Swine vesicular disease
*Address of laboratory:	The Pirbright Institute, Ash Road, Pirbright, Surrey, GU24 0NF, United Kingdom
*Tel:	+441483231021
*E-mail address:	donald.king@pirbright.ac.uk
Website:	https://www.pirbright.ac.uk/
*Name (including Title) of Head of Laboratory (Responsible Official):	Prof. Bryan Charleston
*Name (including Title and Position) of WOA Reference Expert:	Dr Donald King
*Which of the following defines your laboratory? Check all that apply:	Governmental Academic institution

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOA Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
Serology tests (Ab detection ELISA)	Yes	150	0
Direct diagnostic tests			
Real-time RT-PCR	Yes	13	0
Ag-ELISA	Yes	13	0

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?

Yes

Type of reagent available	Related diagnostic testing	Produced/ imported	Quantity supplied nationwide (ml, mg)	Quantity supplied at international level (ml, mg)	Name of beneficiary WOA Member Countries

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA Members?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient WOA Member Countries	Country of recipients
SVDV antigen SVDV control sera	VNT and ELISA	Produced	0	3 ml	1	CHINESE TAIPEI,

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAHA Members?

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAHA Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

9. Did your laboratory validate vaccines according to WOAHA Standards for the designated pathogen or disease?

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAHA Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHA Member?

Yes

Name of the WOAHA Member Country receiving a technical consultancy	Purpose	How the advice was provided
GEORGIA	Assistance for diagnostics	Via email

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHA Members other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	WOAHA Member Countries involved other than your country
Field tests for FMDV, SVDV and other vesicular viruses	4 years	Optimise and validate new assay diagnostic platform	APQA, South Korea	KOREA (REP. OF)

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOAHA?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

2

Dekker A., Knowles N. J., Belsham G. J., Nfon C., Zhang Z., Koenen F., Alexandersen S. and King D. P. (2025) Chapter 40: Picornaviruses. In: Zimmerman J. J., Burrough E. R., Karriker L. A., Schwartz K. J. and Zhang J. Q. (Eds.) *Diseases of Swine, 12th Edition*, Wiley Press.

Bregoli A., Benedetti D., Calzolari M., Benevenia R., Di Nardo A., Castelli A., Corsa M., Grazioli S., Chiapponi C., Brocchi E., Pezzoni G. Genetic evolution of swine vesicular disease viruses circulating in Italy from 1992 to the eradication in 2015 and emergence of a recent recombinant strain. *Virus Evol.* 2025 Sep 6;11(1):veaf066. doi: 10.1093/ve/veaf066.

b) International conferences:

0

c) National conferences:

0

d) Other (Provide website address or link to appropriate information):

0

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAHA Members?

Yes

a) Technical visit : 0

b) Seminars : 0

c) Hands-on training courses: 2

d) Internships (>1 month) 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
C	SPAIN	1
C	SINGAPORE	1

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025	.pdf format	UKAS 4025 16June2025.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Real-time RT-PCR	United Kingdom Accreditation Service
5B7 ELISA	United Kingdom Accreditation Service
VNT	United Kingdom Accreditation Service
Virus isolation	United Kingdom Accreditation Service

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

SVDV infectious material is handled within high-containment facilities at The Pirbright Institute which are licensed by the UK Health and Safety Executive (HSE) under level 4 of the Specific Animal Pathogens Order (UK).

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAHA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAHA?

No

TOR10: NETWORK WITH WOAHP REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAHP Reference Laboratories designated for the same pathogen or disease?

No

24. Are you a member of a network of WOAHP Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHP Reference Laboratories designated for the same pathogen during the past 2 years?

No

We participate in the PT scheme run by ANSES, France (a WOAHP Reference Laboratory for FMD)

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant WOAHP Reference Laboratories
Developing new tools for the diagnosis of vesicular diseases	Testing new ELISA/LFD formats	IZSLER, Italy
Validation of a cartridge-based assays for vesicular diseases	Validation of new RT-PCR assays format	APQA, South Korea

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen during the past 2 years?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the test	WOAHP Member Countries
FMD/SVD diagnostic methods	Participant	30	Virology and serology assays	

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAHP?

No

29. Additional comments regarding your report:

The lack of international samples reflects the non-notifiable status of SVD for WOAHP. However, SVD is still notifiable in many individual countries.